Re Placing

ReNeuron Group plc
28 June 2006


Guildford, UK: 28 June 2006

                               ReNeuron Group plc
                            Announcement of Placing


ReNeuron Group plc (the 'Company') today announces that it has received
commitments in respect of a placing of 5,500,000 new ordinary shares of 10p each
credited as fully paid ('Ordinary Shares') at a price of 13p per share (the 
'Placing'). Collins Stewart Limited acted as nominated adviser and broker to the
Company in connection with the Placing.

In conjunction with the Placing the Company will issue 556,767 new Ordinary
Shares to StemCells, Inc. fully paid up as to nominal value (the 'SCI Issue')
pursuant to the term of the subscription and share exchange agreement between,
inter alia, the Company and StemCells, Inc. dated 5 July 2005 (as amended) and
as more fully described in the admission document published by the Company on 5
August 2005 in connection with the initial admission of the Ordinary Share
capital of the Company to trading on the AIM market of the London Stock Exchange
plc ('AIM').

A total of 6,056,767 Ordinary Shares are expected to be issued pursuant to the
Placing and the SCI Issue will be issued and admitted to trading on AIM on 29
June 2006. Such Ordinary Shares will rank in full for all dividends and
otherwise pari passu with all existing Ordinary Shares.


For further information:

Michael Hunt, Chief Executive Officer
ReNeuron Group plc                                       [phone]

David Yates
Sarah Macleod
Financial Dynamics - Europe                              [phone]

Jonathan Birt, John Capodanno
Financial Dynamics - US                                  [phone]


Note to editors:

ReNeuron is a leading, UK-based adult stem cell therapy business.  The Group is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.

ReNeuron has used its c-mycER(TAM) technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.

The Group's lead stem cell therapy, ReN001 for chronic stroke disability, is in
late pre-clinical development.  Subject to successful completion of pre-clinical
testing, the Company plans to file for approval to commence initial clinical
trials in stroke by the end of 2006, with trials commencing as soon as possible
thereafter.

The Group has also generated pre-clinical efficacy data with its ReN005 stem
cell therapy for Huntington's disease, a rare, genetic and fatal
neurodegenerative disorder that affects around 1 in 10,000 people.  This
programme is in pre-clinical development.

In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.



                      This information is provided by RNS
            The company news service from the London Stock Exchange